Bruce Conklin, the Deputy Director at the Innovative Genomics Institute in San Francisco, is also an Investigator at Gladstone Institutes specializing in cardiovascular disease. Bruce is a Professor at the University of California, San Francisco and a Co-Founder at Tenaya Therapeutics, a biopharmaceutical company focusing on heart failure therapies. With previous experience as a Postdoctoral Fellow and Consultant, Bruce has a strong background in medicine and public health.
1994 - present